TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Cord Blood America Updates Investors on First Quarter 2010 Achievements (PR Newswire) Cord Blood America, Inc. , the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that its co-founder and CEO, Matthew Schissler, reviewed first quarter results and progress in an interview with analyst Francis Gaskins. us.rd.yahoo.com |
Three Trades on FDA, Clinical Trial Binary Events Mike Havrilla submits:Below are some Regulatory Catalyst Index updates for companies with recent FDA and clinical trial related news...Osiris Therapeutics (NASDAQ:OSIR) announced this morning that Health Canada has completed its initial evaluation and issued a priority (180-day) review for PROCHYMAL (remestemcel-L) (mesenchymal stem cells for intravenous infusion), which is seeking approval as an adult stem cell therapy for for the treatment of graft vs. host disease (GvHD).Complete Story » seekingalpha.com |
Seven Companies Complete IPOs This Week, Already Facing Pricing Pressure Renaissance Capital IPO Research submits: A total of seven companies came to market this week, the highest weekly number in roughly three months. However, all seven deals priced below the midpoints of their proposed ranges and trading was lackluster, indicating the IPO market remains shaky after months of broader market volatility. Leading semiconductor company NXP (NXPI) priced its 34 million shares at $14, below the $18-$21 range. With $475 million in gross proceeds, the KKR and Bain-sponsored deal was the fourth largest IPO year-to-date. The former carve-out of Philips fell roughly -2% in its early trading on Friday, which was not surprising given its highly leveraged balance sheet and the lackluster trading by other PE-backed deals. Complete Story » seekingalpha.com |
Endo's Latest Acquisition Builds Out Pain Franchise, Generics Lineup The Burrill Report submits: By Michael FitzhughEndo Pharmaceuticals (ENDP) is buying the privately-held generic pain medications giant Qualitest from Apax Partners for about $1.2 billion. If approved by regulators, the deal would broadly expand the number of Endo's generic medicines under active FDA review and would bolster its portfolio of generic pain management drugs, giving it deeper access to the $15 billion U.S. pain medication market.Complete Story » seekingalpha.com |
Bears Not Done Riding Amylin Down optionMONSTER submits: By Chris McKhann Shares of Amylin Pharmaceuticals (AMLN) lost 50 percent this week after the Food and Drug Administration rejected one of the company's drugs, and option traders appear poised for more downside. Complete Story » seekingalpha.com |